Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.

GUIDANCE:

Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of $11.85 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.